Royal Bank of Canada
HELX icon

Royal Bank of Canada’s Franklin Genomic Advancements ETF HELX Stock Holding History

Royal Bank of Canada’s Portfolio HELX Stock Details HELX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-400
Closed -$12K – 6986
2024
Q4 		$12K Hold
400
– – ﹤0.01% 6291
2024
Q3 		$13K Buy
+400
New +$13.1K ﹤0.01% 6258

Other funds holding HELX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada's HELX Position: Q1 2025 in Review

Royal Bank of Canada sold out of Franklin Genomic Advancements ETF (HELX) in Q1 2025, closing a stake of 400 shares — an estimated $12K sold.

Royal Bank of Canada first reported a position in HELX in Q3 2024 and held it in 2 quarters. The position peaked at $13K in Q3 2024. 8 funds tracked by Wall St. Rank hold HELX as of Q1 2025.

  • Royal Bank of Canada reported no remaining Franklin Genomic Advancements ETF position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 400 Franklin Genomic Advancements ETF shares in Q1 2025, an estimated $12K.
  • Royal Bank of Canada first reported a position in Franklin Genomic Advancements ETF in Q3 2024 and held it in 2 quarters.
  • Royal Bank of Canada's Franklin Genomic Advancements ETF position peaked at $13K in Q3 2024.
  • 8 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.